Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MTOR | P42345 | 14/20 | 0.48 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.47 |
| ▸ | ATR | Q13535 | 2/20 | 0.46 |
| ▸ | ATRIP | Q8WXE1 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | RECQL | P46063 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30882119 | 1.00 | MTOR (0.48) | MTORLRRK2ATRATRIPALDH1A1 | |
| SCHEMBL3291095 | 0.80 | AR (0.52) | LRRK2ALDH1A1MAPTKDM4ERECQL | |
| SCHEMBL250825 | 0.78 | GRM1 (0.46) | MTORLRRK2ATRATRIPKDM4E | |
| SCHEMBL25353367 | 0.77 | MTOR (0.53) | MTORATRATRIP | |
| SCHEMBL25285572 | 0.77 | MTOR (0.53) | MTORATRATRIP | |
| SCHEMBL30454261 | 0.77 | MTOR (0.53) | MTORATRATRIP | |
| SCHEMBL25353363 | 0.77 | MTOR (0.53) | MTORATRATRIP | |
| SCHEMBL23328020 | 0.77 | MTOR (0.47) | MTOR | |
| SCHEMBL23344657 | 0.77 | MTOR (0.47) | MTORATRATRIP | |
| SCHEMBL30455141 | 0.77 | MTOR (0.53) | MTORATRATRIP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3820860-B1 | PYRIDAZINE COMPOUNDS FOR INHIBITING NAV1.8 | LIEBER INST INC (US) | 2025-10-15 | — | — | EP | disclosed |
| US-11993581-B2 | Pyridazine compounds for inhibiting Nav1.8 | LIEBER INSTITUE, INC (US) | 2024-05-28 | — | — | US | disclosed |
| CN-112689629-B | For inhibiting Nav1.8 Pyridazine Compounds | 利伯研究所公司 | 2024-04-23 | — | — | CN | disclosed |
| EP-3820860-A1 | PYRIDAZINE COMPOUNDS FOR INHIBITING NAV1.8 | Lieber Institute, Inc. (US) | 2021-05-19 | — | — | EP | disclosed |
| US-20210139456-A1 | PYRIDAZINE COMPOUNDS FOR INHIBITING NAV1.8 | LIEBER INSTITUTE, INC | 2021-05-13 | — | — | US | disclosed |
| US-20210139456-A1 | PYRIDAZINE COMPOUNDS FOR INHIBITING NAV1.8 | LIEBER INSTITUTE, INC | 2021-05-13 | — | — | US | disclosed |
| CN-112689629-A | For inhibiting Nav1.8 pyridazine Compounds | 利伯研究所公司 | 2021-04-20 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210139456-A1 | PYRIDAZINE COMPOUNDS FOR INHIBITING NAV1.8 | SCN8A, SCN5A, SCN2A | MTOR 3556/4885LRRK2 1681/4885ATR 4736/4885 |
| US-11993581-B2 | Pyridazine compounds for inhibiting Nav1.8 | SCN8A, SCN5A, SCN2A | MTOR 3556/4885LRRK2 1681/4885ATR 4736/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.